Trasylol
Manufactured by Bayer Pharmaceuticals Corporation, Trasylol (aprotinin) is an injectable prescription drug which acts to decrease the risk of bleeding during surgery. The drug is normally administered to patients undergoing heart bypass surgery—specifically cardiopulmonary bypass (CPB) or coronary artery bypass graft (CABG) surgery—to control blood loss and the need for transfusions. Trasylol has also been used in other surgeries such as hip replacement.
In 2006, a public health advisory was issued by the FDA to notify healthcare professionals about the serious risks of Trasylol side effects, including fatal anaphylactic or anaphylactoid reactions.
On November 5, 2007, the FDA announced that Bayer Pharmaceuticals Corp. agreed to a marketing suspension of Trasylol, pending detailed review of preliminary results from a Canadian study that suggested Trasylol use increased risk for death and may increase the risk for clot formation within coronary artery bypass grafts. A further report also found the use of Trasylol doubled the risk of liver damage, kidney failure, heart attack and heart failure, and quadrupled the risk of stroke. Until the FDA, in conjunction with Bayer Pharmaceuticals Corporation, can greater analyze the data from both studies, Trasylol will remain suspended from the market.
If you have had heart surgery such as cardiopulmonary bypass (CPB) or coronary artery bypass graft (CABG) surgery, you may have been administered Trasylol.
If you have suffered kidney failure, heart problems, or other complications after surgery, please contact one of Messa & Associates’ pharmaceutical drug lawyers for a free consultation at 1 877 MESSA LAW.
